FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Friedemann Honecker

Research Profile

Disorders

Chemicals & Drugs

Physiology

Drug Resistance, Neoplasm

Concepts & Ideas

Procedures

Anatomy

Co-author Network

Publications

TOP 3
Annabelle E Fenske; Stephanie Glaesener; Friedemann Honecker; Juergen Thomale; Carsten Bokemeyer; Jochen Dahm-Daphi; Dorothee C Dartsch
Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair.
B Nitzsche; Mark Schrader; F Zengerling; Stefan Balabanov; C Gloesenkamp; B Hoffmann; Friedemann Honecker; Michael Höpfner
Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Sergey A Dyshlovoy; Sergey N Fedorov; Anatoly I Kalinovsky; Larisa K Shubina; Valentin A Stonik; Carsten Bokemeyer; Friedemann Honecker
Mycalamide A shows cytotoxic properties and prevents EGF-induced neoplastic transformation through inhibition of nuclear factors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Friedemann Honecker (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Annabelle E Fenske; Stephanie Glaesener; Friedemann Honecker; Juergen Thomale; Carsten Bokemeyer; Jochen Dahm-Daphi; Dorothee C Dartsch
Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair.
Cancer letters 2012;324(2):171-8.
2012: B Nitzsche; Mark Schrader; F Zengerling; Stefan Balabanov; C Gloesenkamp; B Hoffmann; Friedemann Honecker; Michael Höpfner
Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
British journal of cancer 2012;107(11):1853-63.
2012: Sergey A Dyshlovoy; Sergey N Fedorov; Anatoly I Kalinovsky; Larisa K Shubina; Valentin A Stonik; Carsten Bokemeyer; Friedemann Honecker
Mycalamide A shows cytotoxic properties and prevents EGF-induced neoplastic transformation through inhibition of nuclear factors.
Marine drugs 2012;10(6):1212-24.
2012: Karin Oechsle; Christoph Oing; Lars Arne Berger; Carsten Bokemeyer; Christian Kollmannsberger; Frank Mayer; Friedemann Honecker
Bone metastases in germ cell tumor patients.
Journal of cancer research and clinical oncology 2012;138(6):947-52.
2012: Sergey A Dyshlovoy; Sergey N Fedorov; Manuela Gesell Salazar; Joachim Hauber; Stefan Balabanov; Carsten Bokemeyer; Christine Jacobsen; Marcel Krepstakies; Ina Naeth; Michael Preukschas; Poornima Priyadarshini; Christian Scharf; Larisa K Shubina; Henning Sievert; Valentin A Stonik; Simone Venz; Reinhard Walther; Friedemann Honecker
Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity.
Journal of proteome research 2012;11(4):2316-30.
2011: Karin Oechsle; E Winquist; L Wood; F Mayer; C Bokemeyer; T Cheng; Kim Chi; Piotr M Czaykowski; M Fenner; S Glaesener; J T Hartmann; Friedemann Honecker; C Kollmannsberger
Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(12):2654-60.
2011: Karin Oechsle; Cornelius F Waller; I Boehlke; Carsten Bokemeyer; Jörg T Hartmann; Friedemann Honecker; Christian Kollmannsberger; Frank Mayer
Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
European urology 2011;60(4):850-5.
2011: D Koychev; Karin Oechsle; C Bokemeyer; Friedemann Honecker
Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update.
International journal of andrology 2011;34(4 Pt 2):e266-73.
2011: Frank Mayer; Hendrik Wermann; Peter Albers; hans stoop; Ad J M Gillis; Jörg T Hartmann; C Carsten Bokemeyer; J Wolter Oosterhuis; Leendert H J Looijenga; Friedemann Honecker
Histopathological and molecular features of late relapses in non-seminomas.
BJU international 2011;107(6):936-43.
2011: Jan K Hennigs; Friedemann Honecker; Gunhild Keller; Hans Jörg Baumann; Carsten Bokemeyer; Tim H Brümmendorf; Stefan Kluge; Hans Klose
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
BMC pulmonary medicine 2011;11():30.
2011: Matthias Port; Armin Riecke; Christian Ruf; Carsten Bokemeyer; Stephanie Glaesener; Friedemann Honecker; Viktor Meineke; Michael Abend
Micro-RNA expression in cisplatin resistant germ cell tumor cell lines.
Molecular cancer 2011;10():52.
2010: Hendrik Wermann; hans stoop; Ad J M Gillis; Friedemann Honecker; Ruud van Gurp; Ole Ammerpohl; Julia Richter; J Wolter Oosterhuis; Carsten Bokemeyer; Leendert H J Looijenga
Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance.
The Journal of pathology 2010;221(4):433-42.
2010: Friedemann Honecker; Carsten Bokemeyer
Patients with advanced non-seminomatous germ-cell tumour: the art of the start.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(8):1569-71.
2010: Karin Oechsle; Anja Lorch; Friedemann Honecker; Christian Kollmannsberger; Jörg T Hartmann; Ina Boehlke; Jörg Beyer; Carsten Bokemeyer
Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor.
Oncology 2010;78(1):47-53.
2010: Karin Oechsle; Carsten Bokemeyer; Friedemann Honecker
Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
Journal of cancer research and clinical oncology 2010;136(1):165-7.
2009: Friedemann Honecker; Hendrik Wermann; Frank Mayer; Ad J M Gillis; Hans Stoop; Ruud J L M van Gurp; Karin Oechsle; Ewout Steyerberg; Jörg Thomas Hartmann; Winand N M Dinjens; J Wolter Oosterhuis; Carsten Bokemeyer; Leendert H J Looijenga
Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2129-36.
2009: Marcus Schittenhelm; Christian Kollmannsberger; Karin Oechsle; Amy Harlow; Jason Morich; Friedemann Honecker; Raffael Kurek; Stephan Störkel; Lothar Kanz; Christopher L Corless; Kwok-Kin Wong; Carsten Bokemeyer; Michael C Heinrich
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.
Molecular cancer therapeutics 2009;8(3):481-9.
2009: Friedemann Honecker; Carsten Bokemeyer
[Registries and clinical trials in geriatric oncology in Germany].
Onkologie 2009;32 Suppl 3():14-8.
2008: Stephanie Glaesener; Friedemann Honecker; Imke M Veltman; Ad J M Gillis; Tina Rohlfing; Thomas Streichert; Benjamin Otto; Tim H Brummendorf; Leendert H J Looijenga; Carsten Bokemeyer; Stefan Balabanov
Comparative proteome, transcriptome, and genome analysis of a gonadal and an extragonadal germ cell tumor cell line.
Journal of proteome research 2008;7(9):3890-9.
2008: hans stoop; Friedemann Honecker; G J M van de Geijn; A J M Gillis; M C Cools; M de Boer; Carsten Bokemeyer; K P Wolffenbuttel; S L S Drop; R R de Krijger; N Dennis; Brenda Summersgill; A McIntyre; Janet Shipley; J W Oosterhuis; L H J Looijenga
Stem cell factor as a novel diagnostic marker for early malignant germ cells.
The Journal of pathology 2008;216(1):43-54.
2008: Carsten Bokemeyer; Karin Oechsle; Friedemann Honecker; Frank Mayer; Jörg Thomas Hartmann; C F Waller; I Böhlke; Christian Kollmannsberger
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):448-53.
2007: J Wolter Oosterhuis; hans stoop; Friedemann Honecker; Leendert H J Looijenga
Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives.
International journal of andrology 2007;30(4):256-63; discussion 263-4.
2007: Karin Oechsle; Friedemann Honecker; Christian Kollmannsberger; Oliver Rick; Victor Grünwald; Frank Mayer; Jörg Thomas Hartmann; Carsten Bokemeyer
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Anti-cancer drugs 2007;18(3):273-6.
2007: Adrian R Martineau; Friedemann Honecker; Robert J Wilkinson; Christopher J Griffiths
Vitamin D in the treatment of pulmonary tuberculosis.
The Journal of steroid biochemistry and molecular biology 2007;103(3-5):793-8.
2007: Ulrich Wedding; Friedemann Honecker; Carsten Bokemeyer; Ludger Pientka; Klaus Höffken
Tolerance to chemotherapy in elderly patients with cancer.
Cancer control : journal of the Moffitt Cancer Center 2007;14(1):44-56.
2006: Friedemann Honecker
Normal and malignant germ cell development.
Critical reviews in oncogenesis 2006;12(3-4):297-8; discussion 298-9.
2006: Christian Kollmannsberger; Friedemann Honecker; Carsten Bokemeyer
Treatment of germ cell tumors--update 2006.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x31-5.
2006: Sandra Mueller; Marcus Schittenhelm; Friedemann Honecker; Elke Malenke; Kirsten Lauber; Sebastian Wesselborg; Jörg Thomas Hartmann; Carsten Bokemeyer; Frank Mayer
Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
International journal of oncology 2006;29(2):471-9.
2006: Friedemann Honecker; Tim H Brümmendorf; Oliver Klein; Carsten Bokemeyer
Safe use of oxaliplatin in a patient with metastatic breast cancer and combined renal and hepatic failure.
Onkologie 2006;29(6):273-5.
2006: Christian Kollmannsberger; Marcus Schittenhelm; Friedemann Honecker; J Tillner; D Weber; Karin Oechsle; Lothar Kanz; Carsten Bokemeyer
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(6):1007-13.
2006: Friedemann Honecker; hans stoop; Frank Mayer; Carsten Bokemeyer; Diego H Castrillon; Yun-Fai Chris Lau; Leendert H J Looijenga; J Wolter Oosterhuis
Germ cell lineage differentiation in non-seminomatous germ cell tumours.
The Journal of pathology 2006;208(3):395-400.
2006: Martine Cools; Friedemann Honecker; hans stoop; Joris D Veltman; Ronald R de Krijger; Ewout W Steyerberg; Katja P Wolffenbuttel; Carsten Bokemeyer; Yun-Fai Chris Lau; Stenvert L S Drop; Leendert H J Looijenga
Maturation delay of germ cells in fetuses with trisomy 21 results in increased risk for the development of testicular germ cell tumors.
Human pathology 2006;37(1):101-11.
2005: hans stoop; Friedemann Honecker; Martine Cools; Ronald R de Krijger; Carsten Bokemeyer; Leendert H J Looijenga
Differentiation and development of human female germ cells during prenatal gonadogenesis: an immunohistochemical study.
Human reproduction (Oxford, England) 2005;20(6):1466-76.
2005: Anne-Marie F Kersemaekers; Friedemann Honecker; hans stoop; Martine Cools; Michel Molier; Katja P Wolffenbuttel; Carsten Bokemeyer; Yunmin Li; Yun-Fai Chris Lau; J Wolter Oosterhuis; Leendert H J Looijenga
Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPY.
Human pathology 2005;36(5):512-21.
2004: Friedemann Honecker; Ulrich Wedding; Carsten Bokemeyer
Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC).
Onkologie 2004;27(6):583-8.
2004: Friedemann Honecker; Ulrich Wedding; Carsten Bokemeyer
Chemotherapy in elderly patients with advanced lung cancer. Part I: General aspects and treatment of small cell lung cancer (SCLC).
Onkologie 2004;27(5):500-5.
2004: Friedemann Honecker; Anne-Marie F Kersemaekers; Michel Molier; Pascale C van Weeren; hans stoop; Ronald R de Krijger; Katja P Wolffenbuttel; Wolter Oosterhuis; Carsten Bokemeyer; Leendert H J Looijenga
Involvement of E-cadherin and beta-catenin in germ cell tumours and in normal male fetal germ cell development.
The Journal of pathology 2004;204(2):167-74.
2004: Friedemann Honecker; hans stoop; Ronald R de Krijger; Yun-Fai Chris Lau; Carsten Bokemeyer; Leendert H J Looijenga
Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells.
The Journal of pathology 2004;203(3):849-57.
2004: Friedemann Honecker; J Wolter Oosterhuis; Frank Mayer; Jörg Thomas Hartmann; Carsten Bokemeyer; Leendert H J Looijenga
New insights into the pathology and molecular biology of human germ cell tumors.
World journal of urology 2004;22(1):15-24.
2003: S Koch; Frank Mayer; Friedemann Honecker; Marcus Schittenhelm; Carsten Bokemeyer
Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro.
British journal of cancer 2003;89(11):2133-9.
2003: Jörg Thomas Hartmann; Karin Oechsle; Detlef Quietzsch; Axel Wein; Ralf-Dieter Hofheinz; Friedemann Honecker; O Nehls; Claus-Henning Köhne; G Käfer; Lothar Kanz; Carsten Bokemeyer
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
British journal of cancer 2003;89(11):2051-6.
2003: Friedemann Honecker; Frank Mayer; hans stoop; J Wolter Oosterhuis; Sandra Koch; Carsten Bokemeyer; Leendert H J Looijenga
Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors.
Laboratory investigation; a journal of technical methods and pathology 2003;83(10):1489-95.
2003: Frank Mayer; Friedemann Honecker; Leendert H J Looijenga; Carsten Bokemeyer
Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):825-32.
2003: Leendert H J Looijenga; hans stoop; Hubert P J C de Leeuw; Carlos A de Gouveia Brazao; Ad J M Gillis; Kees E P van Roozendaal; Everardus J J van Zoelen; R F A Weber; Katja P Wolffenbuttel; Herman van Dekken; Friedemann Honecker; Carsten Bokemeyer; Elizabeth J. Perlman; Dominik Schneider; Juha Kononen; Guido Sauter; J Wolter Oosterhuis
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors.
Cancer research 2003;63(9):2244-50.
2003: Friedemann Honecker; Claus-Henning Köhne; Carsten Bokemeyer
Colorectal cancer in the elderly: is palliative chemotherapy of value?
Drugs & aging 2003;20(1):1-11.
2002: Friedemann Honecker; Christian Kollmannsberger; Detlef Quietzsch; Caroline Haag; M Schroeder; C Spott; Jörg Thomas Hartmann; W Baronius; V Hempel; Lothar Kanz; Carsten Bokemeyer
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Anti-cancer drugs 2002;13(5):497-503.
2002: Carsten Bokemeyer; Friedemann Honecker; Ulrich Wedding; Ernst Späth-Schwalbe; H P Lipp; G Kolb
Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy.
Onkologie 2002;25(1):32-9.
2002: Friedemann Honecker; G Kolb; Carsten Bokemeyer
[Therapy of elderly patients with colorectal carcinoma].
Wiener medizinische Wochenschrift (1946) 2002;152(7-8):170-6.
2001: Friedemann Honecker; Ulrich Wedding; G Kolb; Carsten Bokemeyer
[Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?].
Onkologie 2001;24(1):87-94.